

BCG vaccine**Section**

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tuberculosis

Ebola vaccine**Section**

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Japanese encephalitis vaccine**Section**

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Medicines for COVID-19**Section**

Medicines for COVID-19

- Refer to WHO living guidelines

Indications

COVID-19

Abacavir**Section**

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + dolutegravir + lamivudine**Section**

Fixed-dose combinations of antiretrovirals

- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + lamivudine

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

Abiraterone

Section

Hormones and antihormones

- Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Acamprosate calcium

Section

Medicines for alcohol use disorders

- Oral > Solid > tablet: 333 mg

Indications

Disorders due to use of alcohol

Acenocoumarol

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [warfarin](#) for

Venous thromboembolism

Therapeutic equivalent to [warfarin](#) for

Cerebral ischaemic stroke due to embolic occlusion

Therapeutic equivalent to [warfarin](#) for

Atrial fibrillation

Therapeutic equivalent to [warfarin](#) for

Other specified diseases of arteries or arterioles

Acetazolamide

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Oral > Solid: 250 mg

Indications

Primary open-angle glaucoma

Acetic acid

Section

Ear, nose and throat medicines [c]

- Local > Otological > drops: 2% solution

Indications

Infectious diseases of external ear

Acetylcysteine

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
- Oral > Liquid: 10%; 20%

Indications

Acute or subacute hepatic failure

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Acetylsalicylic acid

Section

Medicines for acute migraine attacks

- Oral > Solid: 300 to 500 mg

Anti-platelet medicines

- Oral > Solid: 100 mg

Medicines for juvenile joint diseases

- Local > Rectal > Suppository: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg
- Oral > Solid > tablet: 75 to 500 mg

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg

Indications

Migraine

Acute myocardial infarction

Cerebral ischaemic stroke

Mucocutaneous lymph node syndrome

Juvenile idiopathic arthritis

Acute rheumatic fever without mention of heart involvement

Pain

Acetylsalicylic acid + atorvastatin + ramipril

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

- Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg

Indications

Atherosclerotic chronic arterial occlusive disease

Chronic ischaemic heart disease

Cerebral ischaemic stroke

Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease ◦ Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Aciclovir

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Ointment: 3% w/w	Herpes simplex keratitis
Antiherpes medicines ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)	Zoster Herpes simplex infections Varicella
Medicines for viral central nervous system infections ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)	Zoster Herpes simplex infections Varicella

Acridinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

Activated charcoal

Section	Indications
Antidotes and other substances used in poisonings > Non-specific ◦ Oral > Liquid: 50 mg granules for oral suspension	Unspecified injury, poisoning or certain other consequences of external causes

Adalimumab

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

Axial spondyloarthritis

Crohn disease site

Rheumatoid arthritis

Juvenile idiopathic arthritis

Psoriasis of unspecified type

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for

Other specified malignant neoplasms of bronchus or lung

Albendazole

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 400 mg (chewable, scored)

Cysticidal medicines

- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)

Antifilarials

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

Echinococcosis

Cysticercosis

Hookworm diseases

Trichuriasis

Ascariasis

Enterobiasis

Other specified echinococcosis

Cysticercosis of central nervous system

Lymphatic filariasis

Alcohol based hand rub

Section

Disinfectants

- Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol

Indications

Denatured alcohol

Alcuronium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)

Indications

Muscle relaxants

Alfacalcidol

Section

Medicines for endocrine disorders

- Oral > Liquid: 2 µg per mL
- Oral > Solid > capsule: 0.25 µg; 1 µg

Indications

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

All-trans retinoic acid

Section

Targeted therapies

- Oral > Solid: 10 mg capsule

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section

Medicines used to treat gout

- Oral > Solid: 100 mg

Supportive medicines

- Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
- Oral > Solid: 100 mg; 300 mg

Indications

Gout

Tumour lysis syndrome

Alprostadi (prostaglandin E1)

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 0.5 mg per mL in alcohol

Indications

Other specified congenital anomaly of great arteries including arterial duct

Alteplase

Section

Thrombolytic medicines

- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Cerebral ischaemic stroke

Amidotrizoate

Section

Diagnostic agents > Radiocontrast media

- Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

Indications

Amidotrizoate

Amikacin

Section

Ophthalmological preparations > Anti-infective agents

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

Access group antibiotics

- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

First choice

Neutropaenia (high-risk)

co-prescribed with [cefotaxime](#)

Acute pyelonephritis (severe)

co-prescribed with [cefotaxime](#)

Inflammatory or other diseases of prostate (severe)

co-prescribed with [ceftriaxone](#)

Acute pyelonephritis (severe)

co-prescribed with [ceftriaxone](#)

Inflammatory or other diseases of prostate (severe)

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Multi-drug resistant *Mycobacterium tuberculosis*

Amiloride

Section

Diuretics

- Oral > Solid: 5 mg (hydrochloride)

Indications

Oedema

Ascites

Amiodarone

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Cardiac arrhythmia

Amitriptyline

Section

Medicines for migraine prophylaxis

- Oral > Solid > tablet: 25 mg

Medicines for other common symptoms in palliative care

- Oral > Liquid: 25 mg per 5 mL
- Oral > Solid > tablet: 25 mg; 10 mg; 75 mg

Medicines for depressive disorders

- Oral > Solid: 25 mg; 75 mg

Indications

Migraine

Palliative care

Depressive disorders

Amlodipine

Section

Antihypertensive medicines

- Oral > Solid: 5 mg (as maleate, mesylate or besylate)

Indications

Essential hypertension

Amodiaquine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Amodiaquine - sulfadoxine + pyrimethamine

Section

[Antimalarial medicines](#) > [Medicines for chemoprevention](#)

- Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package

Indications

Malaria

Section	Indications
Access group antibiotics - Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid - Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection - Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) - Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) - Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) - Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	First choice - Acute pharyngitis - Periapical abscess without sinus - Acute sinusitis - Acute otitis media - Chronic obstructive pulmonary disease with acute exacerbation - Acute malnutrition in infants, children or adolescents (uncomplicated) [children] - Acute malnutrition in infants, children or adolescents (complicated) [children] - Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin - Sepsis without septic shock Second choice - Bacterial meningitis Other indications - Bacterial infection of unspecified site - Infectious cystitis
Medicines for bacterial central nervous system infections - Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid - Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection - Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) - Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	Second choice Bacterial meningitis

Amoxicillin + clavulanic acid

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Acute sinusitis

Other specified pneumonia (Hospital-acquired pneumonia)

Chronic obstructive pulmonary disease with acute exacerbation

Neutropaenia (low-risk)

Peritoneal abscess (mild-moderate)

Peritonitis (mild-moderate)

Infectious cystitis

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Bacterial pneumonia (Community-acquired pneumonia - severe)

Bacterial infection of joint

Acute otitis media

Other specified prophylactic measures

Osteomyelitis or osteitis

Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)	Candidosis Blastomycosis Cryptococcosis Coccidioidomycosis Aspergillosis Sporotrichosis Histoplasmosis
Antileishmaniasis medicines Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)	Visceral leishmaniasis

Ampicillin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with [gentamicin](#)

Sepsis without septic shock

co-prescribed with [gentamicin](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [gentamicin](#)

Peritoneal abscess (severe)

co-prescribed with [gentamicin](#)

Peritonitis (mild-moderate)

co-prescribed with [gentamicin](#)

Peritonitis (severe)

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Second choice

Bacterial meningitis

Anakinra

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Anastrozole

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 1 mg tablet	Malignant neoplasms of breast Other specified malignant neoplasms of breast
Ovulation inducers ◦ Oral > Solid: 1 mg tablet	Therapeutic equivalent to letrozole for Female infertility without specification whether primary or secondary

Anidulafungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin for Systemic or invasive candidosis

Ansuvimab

Section	Indications
Medicines for Ebola virus disease ◦ Parenteral > General injections > IV: 400 mg powder for injection	Ebola virus disease

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 250 µg in single-dose vial ◦ Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies Rh incompatibility reaction

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 150 IU per mL in vial ◦ Parenteral > Locoregional injections > Other: 150 IU per mL in vial	Rabies

Anti-rabies virus monoclonal antibodies

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)	Rabies

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 500 IU in vial	Tetanus

Antirabies hyperimmune serum

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule	Rabies

Antivenom immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Antivenom sera

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Other specified atrial fibrillation Therapeutic equivalent to dabigatran for Venous thromboembolism

Aprepitant

Section

Antiemetic medicines

- Oral > Liquid: 125 mg powder for oral suspension (in sachet)
- Oral > Solid > capsule: 80 mg; 125 mg; 165 mg

Indications

Nausea or vomiting

Aripiprazole

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension

Indications

Therapeutic equivalent to [risperidone](#) for

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to [paliperidone](#) for

Schizophrenia or other primary psychotic disorders

Arpraziquantel

Section

Antischistosomals and other antitremaatode medicines

- Oral > Solid > dispersible tablet: 150 mg

Indications

Therapeutic equivalent to [praziquantel](#) for

Schistosomiasis

Arsenic trioxide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Artemether

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artemether + lumefantrine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 120 mg
- Oral > Solid > tablet: 20 mg + 120 mg

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artesunate

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
- Local > Rectal > Other: 100 mg capsules

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + amodiaquine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + mefloquine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + pyronaridine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)
- Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate - sulfadoxine + pyrimethamine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Ascorbic acid

Section

Vitamins and minerals

- Oral > Solid: 50 mg

Indications

Scurvy

Asparaginase

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
- Powder for injection: 10 000 IU in vial.

Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of unspecified sites

Atazanavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Atazanavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Atenolol

Section

Antianginal medicines

- Oral > Solid: 50 mg; 100 mg

Antihypertensive medicines

- Oral > Solid: 50 mg; 100 mg

Indications

Angina pectoris

Essential hypertension

Therapeutic equivalent to [bisoprolol](#) for

Essential hypertension

Atezolizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of bronchus or lung

Atoltivimab + maftivimab + odesivimab

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

Ebola virus disease

Atorvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Atorvastatin + perindopril + amlodipine

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

- Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg

Indications

Atherosclerotic chronic arterial occlusive disease

Chronic ischaemic heart disease

Cerebral ischaemic stroke

Atracurium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 10 mg per mL (besylate)

Indications

Therapeutic equivalent to [vecuronium](#) for

Muscle relaxants

Muscle relaxants

Atropine

Section	Indications
Diagnostic agents > Ophthalmic medicines	Therapeutic equivalent to tropicamide for Cycloplegic drug
Ophthalmological preparations > Mydriatics Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)	Anterior uveitis
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)	Exposure to or harmful effects of undetermined intent of pesticides
Preoperative medication and sedation for short-term procedures Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)	Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Axicabtagene ciloleucel

Section	Indications
Antineoplastics and supportive medicines Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.	Diffuse large B-cell lymphomas

Axitinib

Section	Indications
Targeted therapies Oral > Solid > tablet: 1 mg; 3 mg; 5 mg	Renal cell carcinoma of kidney, except renal pelvis

Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Azathioprine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 50 mg (scored)

Immunomodulators for non-malignant disease

- Oral > Solid > tablet: 50 mg (scored)
- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)

Indications

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

Relapsing-remitting multiple sclerosis

Failure or rejection of transplanted organs or tissues

Azithromycin

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

Cholera

Cholera [children]

Paratyphoid fever

Chlamydia trachomatis

Typhoid fever

Yaws

Trachoma

co-prescribed with ceftriaxone

Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

Trachoma

Aztreonam

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Baclofen

Section

Medicines for cerebral palsy

- Oral > Liquid: 10 mg per 5 mL
- Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule
- Oral > Solid > tablet: 10 mg

Indications

Spastic cerebral palsy

Barium sulfate

Section

Diagnostic agents > Radiocontrast media

- Oral > Liquid: Aqueous suspension

Indications

Barium sulfate with suspending agents

Beclometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

Indications

Asthma

Therapeutic equivalent to [budesonide](#) for

Asthma

Beclometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

Bedaquiline

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Beinaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Bendamustine

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Benzathine benzylpenicillin

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection

Indications

First choice

Congenital syphilis [children]

Syphilis

Other indications

Bacterial infection of unspecified site

Benznidazole

Section

American trypanosomiasis

- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

Indications

Chagas disease

Benzoic acid + salicylic acid

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Cream: 6% + 3%
- Local > Topical > Ointment: 6% + 3%

Indications

Fungal infection of the skin

Benzoyl peroxide

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%

Indications

Acne

Benzyl benzoate

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Lotion: 25%

Indications

Pediculosis corporis

Pediculosis capitis

Pthiriasis

Scabies

Benzylpenicillin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Congenital syphilis [children]

Syphilis

co-prescribed with gentamicin

Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Second choice

Bacterial meningitis

Beractant

Section

Medicines administered to the neonate [c]

- Respiratory > Suspension: 25 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

Betamethasone

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)

Indications

Dermatitis or eczema

Pruritus due to skin disorder

Psoriasis of unspecified type

Lichen planus

Bevacizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Hepatocellular carcinoma of liver

Age-related macular degeneration

Bicalutamide

Section

Hormones and antihormones

- Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

Biperiden

Section

Medicines for parkinsonism

- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
- Oral > Solid: 2 mg tablet (hydrochloride)

Indications

Parkinson disease

Bisacodyl

Section

Laxatives

Indications

Therapeutic equivalent to [senna](#) for

Constipation

Bisoprolol

Section	Indications
Antianginal medicines ◦ Oral > Solid: 1.25 mg; 5 mg	Angina pectoris
Antihypertensive medicines ◦ Oral > Solid: 1.25 mg; 5 mg	Essential hypertension
Medicines for migraine prophylaxis ◦ Oral > Solid: 1.25 mg; 5 mg	Migraine
Antiarrhythmic medicines ◦ Oral > Solid: 1.25 mg; 5 mg	Cardiac arrhythmia
Medicines used in heart failure ◦ Oral > Solid: 1.25 mg; 5 mg	Heart failure

Bleomycin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Kaposi sarcoma of unspecified primary site
	Germ cell tumour of testis
	Other specified malignant neoplasms of the ovary
	Unspecified malignant neoplasms of unspecified sites
	Hodgkin lymphoma

Blinatumomab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial	B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Bortezomib

Section	Indications
Targeted therapies ◦ Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Brexpiprazole

Section	Indications
Medicines for depressive disorders ◦ Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg	Depressive disorders

Bromocriptine

Section

Medicines for central nervous system disorders

- Oral > Solid: 2.5 mg; 5 mg

Medicines for disorders of the pituitary hormone system

Indications

Parkinson disease

Therapeutic equivalent to [cabergoline](#) for

Other specified benign neoplasm of endocrine glands

Budesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler
- Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler

Ear, nose and throat medicines [c]

- Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation

Indications

Asthma

Allergic rhinitis

Budesonide + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler

Indications

Asthma

Budesonide + salmeterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

Bumetanide

Section

Diuretics

Medicines used in heart failure

Indications

Therapeutic equivalent to [furosemide](#) for

Anuria or oliguria

Therapeutic equivalent to [furosemide](#) for

Oedema

Therapeutic equivalent to [furosemide](#) for

Heart failure

Bupivacaine

Section

Local anaesthetics

- Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution
- Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)

Indications

Local anaesthetics

Buprenorphine

Section

Medicines for opioid use disorders

Indications

Therapeutic equivalent to [methadone](#) for

Opioid dependence

Bupropion

Section

Medicines for nicotine use disorders

- Oral > Solid: 150 mg sustained-release (hydrochloride)

Indications

Nicotine dependence

C1 esterase inhibitor

Section

Human immunoglobulins

- Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

Hereditary angioedema

Cabergoline

Section

Medicines for disorders of the pituitary hormone system

- Oral > Solid > tablet: 0.5 mg; 1 mg

Medicines for central nervous system disorders

- Oral > Solid > tablet: 0.5 mg

Indications

Other specified benign neoplasm of endocrine glands

Parkinson disease

Caffeine citrate

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
- Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Indications

Apnoea of newborn

Calamine

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

- Local > Topical > Lotion:

Indications

Pruritus

Calcipotriol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 50 µg per mL (0.005%)
- Local > Topical > Lotion: 50 µg per mL (0.005%)
- Local > Topical > Ointment: 50 µg per mL (0.005%)

Indications

Psoriasis of unspecified type

Calcitriol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Medicines for endocrine disorders

- Oral > Solid > capsule: 0.25 µg; 0.5 µg

Indications

Therapeutic equivalent to [calcipotriol](#) for

Psoriasis of unspecified type

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

Calcium

Section

Vitamins and minerals

- Oral > Solid: 500 mg (elemental calcium)

Indications

Calcium deficiency

Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Indications

Burkitt lymphoma including Burkitt leukaemia

Osteosarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Unspecified malignant neoplasms of unspecified sites

Malignant trophoblastic neoplasms of placenta

Calcium gluconate

Section

Vitamins and minerals

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)

Indications

Tetany due to acute calcium deficiency

Hypermagnesaemia

Canagliflozin

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

Capecitabine

Section

Cytotoxic medicines

- Oral > Solid > tablet: 150 mg; 500 mg

Indications

Malignant neoplasms of rectum

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Other specified malignant neoplasms of breast

Capreomycin

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Captopril

Section

Medicines used in heart failure

- Oral > Solid: 25 mg

Indications

Heart failure

Carbachol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Indications

Therapeutic equivalent to [pilocarpine](#) for

Acute angle closure with pupillary block

Therapeutic equivalent to [pilocarpine](#) for

Ocular hypertension

Therapeutic equivalent to [pilocarpine](#) for

Primary open-angle glaucoma

Carbamazepine

Section

Antiseizure medicines

- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

Medicines for neurological disorders

- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
- Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)

Medicines for bipolar disorders

- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg

Indications

Epilepsy or seizures

Trigeminal neuralgia

Bipolar or related disorders

Carbetocin

Section

Uterotonics

- Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to [methimazole](#) for

Thyrotoxicosis

Carboplatin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Osteosarcoma of bone or articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant neoplasms of nasopharynx

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of breast

Retinoblastoma

Malignant neoplasms of kidney, except renal pelvis

Carmellose

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to [hypromellose](#) for

Keratoconjunctivitis sicca

Carvedilol

Section	Indications
Antianginal medicines	Therapeutic equivalent to bisoprolol for Angina pectoris
Antihypertensive medicines	Therapeutic equivalent to bisoprolol for Essential hypertension
Antiarrhythmic medicines	Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
Medicines used in heart failure	Therapeutic equivalent to bisoprolol for Heart failure

Caspofungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin for Systemic or invasive candidosis

Cefalexin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) ◦ Oral > Solid > dispersible tablet: 125 mg; 250 mg ◦ Oral > Solid: 250 mg (as monohydrate)	First choice Bacterial cellulitis, erysipelas or lymphangitis Second choice Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis Other indications Bacterial infection of unspecified site

Cefazolin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures

co-prescribed with metronidazole

Other specified prophylactic measures

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Other indications

Surgical site infection

Cefepime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefiderocol

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Cefixime

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with azithromycin

Gonococcal infection

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Acute pyelonephritis (severe)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

co-prescribed with amikacin

Inflammatory or other diseases of prostate (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritonitis (severe)

Second choice

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Bacterial infection of joint

Inflammatory or other diseases of prostate (mild to moderate)

Osteomyelitis or osteitis

Other indications

Bacterial infection of unspecified site

First choice

Bacterial meningitis

Ceftaroline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

Endophthalmitis

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Ceftazidime + avibactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Ceftolozane + tazobactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Ceftriaxone

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Acute pyelonephritis (severe)

Paratyphoid fever

Typhoid fever

Endophthalmitis

Bacterial pneumonia (Community-acquired pneumonia - severe)

- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Bacterial meningitis

co-prescribed with [amikacin](#)

Inflammatory or other diseases of prostate (severe)

co-prescribed with [azithromycin](#)

Gonococcal infection

co-prescribed with [metronidazole](#)

Necrotising fasciitis

co-prescribed with [metronidazole](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [metronidazole](#)

Peritoneal abscess (severe)

co-prescribed with [metronidazole](#)

Peritonitis (mild-moderate)

co-prescribed with [metronidazole](#)

Peritonitis (severe)

Second choice

Acute pyelonephritis (mild to moderate)

Bacterial infection of joint

Sepsis without septic shock

Infectious gastroenteritis or colitis without specification of infectious agent

Inflammatory or other diseases of prostate (mild to moderate)

Osteomyelitis or osteitis

Other indications

Bacterial infection of unspecified site

First choice

Bacterial meningitis

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Cefuroxime

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Cemiplimab

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Cetirizine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to [loratadine](#) for

Allergic or hypersensitivity conditions of unspecified type

Chlorambucil

Section

Cytotoxic medicines

- Oral > Solid: 2 mg tablet

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Unspecified malignant neoplasms of unspecified sites

Chloramphenicol

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Medicines for bacterial central nervous system infections

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Indications

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Second choice

Bacterial meningitis

Chlorhexidine

Section

Medicines administered to the neonate [c]

- Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
- Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Antiseptics

- Local > Topical > Solution: 5% (digluconate) for dilution

Indications

Omphalitis of newborn

Chlorhexidine

Chlorine base compound

Section

Disinfectants

- Local > Topical > Powder: 0.1% available chlorine for solution
- Local > Topical > Liquid: 0.1% available chlorine for solution
- Local > Topical > Solid: 0.1% available chlorine for solution

Indications

Disinfectant, not elsewhere classified

Chloroquine

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium malariae*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Rheumatoid arthritis

Malaria due to *Plasmodium vivax*

Chlorothiazide

Section

Antihypertensive medicines

Medicines used in heart failure

Indications

Therapeutic equivalent to *hydrochlorothiazide* for

Essential hypertension

Therapeutic equivalent to *hydrochlorothiazide* for

Heart failure

Chloroxylonol

Section

Disinfectants

- Local > Topical > Solution: 4.8%

Indications

Phenol disinfectant, not elsewhere classified

Chlorpromazine

Section

Medicines for psychotic disorders

- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Therapeutic equivalent to [haloperidol](#) for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Chlortalidone

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for

Essential hypertension

Medicines used in heart failure

Therapeutic equivalent to [hydrochlorothiazide](#) for

Heart failure

Chlortetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [tetracycline](#) for

Other specified conjunctivitis

Therapeutic equivalent to [tetracycline](#) for

Infectious keratitis

Therapeutic equivalent to [tetracycline](#) for

Infectious blepharitis

Therapeutic equivalent to [tetracycline](#) for

Trachoma

Cholera vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against cholera alone

Ciclesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

Ciclopirox

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)

Indications

Onychomycosis

Ciclosporin

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

Cimetidine

Section

Antiulcer medicines

- Oral > Solid: 200 mg
- Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Ciprofloxacin

Section

Ear, nose and throat medicines [c]

- Local > Otological > drops: 0.3% (as hydrochloride)

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
- Oral > Solid: 250 mg (as hydrochloride)

Indications

Infectious diseases of external ear

First choice

Acute pyelonephritis (mild to moderate)

Paratyphoid fever

Typhoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Neutropaenia (low-risk)

Inflammatory or other diseases of prostate (mild to moderate)

Second choice

Cholera

Cholera [children]

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

Bacterial infection of unspecified site

Cisplatin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Other specified gliomas of brain

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Malignant neoplasms of hypopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone or articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Malignant neoplasms of nasopharynx

Other specified malignant neoplasms of bronchus or lung

Unspecified malignant neoplasms of unspecified sites

Citalopram

Section

Medicines for anxiety disorders

Indications

Therapeutic equivalent to fluoxetine for

Generalised anxiety disorder

Cladribine

Section

Medicines for multiple sclerosis

- Oral > Solid > tablet: 10 mg

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Multiple sclerosis

Langerhans cell histiocytosis

Clarithromycin

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescribed with [ceftriaxone](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choice

[Acute pharyngitis](#)

co-prescribed with [amoxicillin + clavulanic acid](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)

Clindamycin

Section

Access group antibiotics

- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Indications

First choice

[Necrotising fasciitis](#)

Second choice

[Bacterial infection of joint](#)

[Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Clofazimine

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

[Multi-drug resistant Mycobacterium tuberculosis](#)

Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

[Leprosy](#)

Clomifene

Section

Ovulation inducers

- Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

Clomipramine

Section

Medicines for obsessive compulsive disorders

- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Obsessive-compulsive disorder

Clonazepam

Section

Medicines for central nervous system disorders

- Oral > Solid: 500 µg

Indications

Generalised myoclonic seizure

Clopidogrel

Section

Anti-platelet medicines

- Oral > Solid: 75 mg; 300 mg

Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

Clotrimazole

Section

Antifungal medicines

- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

Vulvovaginal candidosis

Cloxacillin

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Indications

First choice

Bacterial infection of joint

Osteomyelitis or osteitis

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Clozapine

Section

Medicines for psychotic disorders

- Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

Indications

Schizophrenia or other primary psychotic disorders

Coagulation factor IX complex

Section

Coagulation factors

Indications

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Haemophilia B

Coagulation factor IX, plasma-derived

Section

Coagulation factors

- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

Coagulation factor IX, recombinant

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia B

Coagulation factor VIII, plasma-derived

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Haemophilia A

Coagulation factor VIII, recombinant

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia A

Coal tar

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 5%

Indications

Psoriasis of unspecified type

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

Codeine

Section

Antitussives

- Oral > Solid: 10 mg tablet (codeine phosphate)

Opioid analgesics

- Oral > Solid: 30 mg tablet (codeine phosphate)

Medicines for diarrhoea

- Oral > Solid: 30 mg tablet (codeine phosphate)

Indications

Cough

Pain

Diarrhoea

Colchicine

Section

Medicines used to treat gout

- Oral > Solid: 0.5 mg

Indications

Gout

Colecalciferol

Section

Vitamins and minerals

- Oral > Liquid: 400 IU per mL
- Oral > Solid: 400 IU; 1000 IU

Indications

Calcium deficiency

Vitamin D deficiency

Therapeutic equivalent to [ergocalciferol](#) for

Calcium deficiency

Therapeutic equivalent to [ergocalciferol](#) for

Vitamin D deficiency

Colistin (injection)

Section	Indications
Reserve group antibiotics - Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) - Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Other specified bacterial diseases Carbapenem resistant <i>Acinetobacter baumannii</i> Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Other carbapenem resistant Enterobacterales Carbapenem resistant <i>Klebsiella pneumoniae</i> Carbapenem resistant <i>Escherichia coli</i>

Compound sodium lactate solution

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral Parenteral > General injections > IV: injectable solution	Hypovolaemic shock Other specified disorders of fluid, electrolyte or acid-base balance

Condoms

Section	Indications
Barrier methods -	Contact with health services for contraceptive management

Copper-containing intrauterine device

Section	Indications
Intrauterine devices -	Contact with health services for insertion of contraceptive device

Crizotinib

Section	Indications
Targeted therapies - Oral > Solid > capsule: 200 mg; 250 mg - Oral > Solid: 200 mg; 250 mg	Anaplastic large cell lymphoma, ALK-positive Other specified malignant neoplasms of bronchus or lung

Cryoprecipitate (native)

Section

Blood and blood components

Indications

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for

Obstetric haemorrhage

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for

Haemophilia A

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for

Von Willebrand disease

Cryoprecipitate (pathogen-reduced)

Section

Blood and blood components

- Injection: frozen liquid in bag or lyophilized powder in vial containing:
 - > 50 IU Factor VIII
 - > 100 IU vWF
 - > 140 mg clottable fibrinogen per unit

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Obstetric haemorrhage

Haemophilia A

Von Willebrand disease

Cyanocobalamin

Section

Antianaemia medicines

- .

Indications

Anaemias or other erythrocyte disorders

Cyclizine

Section

Medicines for other common symptoms in palliative care

- Parenteral > General injections > unspecified: 50 mg per mL (lactate)
- Oral > Solid > tablet: 50 mg (hydrochloride)

Indications

Palliative care

Cyclopentolate

Section

Diagnostic agents > Ophthalmic medicines

Ophthalmological preparations > Mydriatics

Indications

Therapeutic equivalent to [tropicamide](#) for

Cycloplegic drug

Therapeutic equivalent to [atropine](#) for

Anterior uveitis

Cyclophosphamide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg
- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Indications

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Other specified gliomas of brain

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Cycloserine

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Cytarabine

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Unspecified malignant neoplasms of unspecified sites

Cytisine (cytisinicline)

Section

Medicines for nicotine use disorders

- Oral > Solid > tablet: 1.5 mg

Indications

Nicotine dependence

Dabigatran

Section

Medicines affecting coagulation

- Oral > Solid: 110 mg; 150 mg

Indications

Other specified atrial fibrillation

Venous thromboembolism

Dabrafenib

Section

Targeted therapies

- Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dacarbazine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Daclatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

Chronic hepatitis C

Daclatasvir + sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

Chronic hepatitis C

Dactinomycin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of unspecified sites

Malignant trophoblastic neoplasms of placenta

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Dalteparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for

Acute ischaemic heart disease

Therapeutic equivalent to [enoxaparin](#) for

Venous thromboembolism

Dapagliflozin

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for

Type 2 diabetes mellitus

Dapsone

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

Leprosy

Daptomycin

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

Daratumumab

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

Darbepoetin alfa

Section

Antianaemia medicines

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for

Anaemia due to chronic disease

Supportive medicines

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for

Drug-induced aplastic anaemia

Darunavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dasabuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 250 mg tablet

Indications

Chronic hepatitis C

Dasatinib

Section

Targeted therapies

- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myelogenous leukaemia, BCR-ABL1-positive

Daunorubicin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Deferasirox

Section	Indications
Medicines for haemoglobinopathies ◦ Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg ◦ Oral > Solid > tablet: 90 mg; 180 mg; 360 mg	Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias

Deferiprone

Section	Indications
Medicines for haemoglobinopathies	Therapeutic equivalent to deferiasirox for Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferiasirox for Thalassaemias

Deferoxamine

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)	Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
Medicines for haemoglobinopathies ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)	Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias

Delafloracin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 300 mg lyophilized powder for injection ◦ Oral > Solid: 450 mg	Methicillin resistant Staphylococcus aureus

Delamanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 25 mg ◦ Oral > Solid > tablet: 50 mg	Multi-drug resistant Mycobacterium tuberculosis

Dengue vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Desmopressin

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 150 µg per actuation (acetate)

Indications

Haemophilia A

Von Willebrand disease

Dexamethasone

Section

Other medicines administered to the mother

- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Hormones and antihormones

- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 4 mg (as dexamethasone base)

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

Medicines for other common symptoms in palliative care

Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Anaplastic large cell lymphoma, ALK-negative

Lymphoid leukaemia, not elsewhere classified

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-positive

Allergic or hypersensitivity conditions of unspecified type

Palliative care

- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equivalent to 3.3 mg dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)

Antiemetic medicines

- Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)

Nausea or vomiting

Dextran 40

Section

Plasma substitutes

- .

Indications

Hypovolaemia

Dextran 70

Section

Plasma substitutes

- Parenteral > General injections > IV: 6% injectable solution

Indications

Hypovolaemia

Diaphragms

Section

Barrier methods

- -

Indications

Contact with health services for contraceptive management

Diazepam

Section

Antiseizure medicines

- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Medicines for other common symptoms in palliative care

- Oral > Liquid: 2 mg per 5 mL
- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
- Parenteral > General injections > unspecified: 5 mg per mL
- Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)

Medicines for anxiety disorders

- Oral > Solid: 5 mg (scored); 2 mg (scored)

Indications

Therapeutic equivalent to [lorazepam](#) for

Status epilepticus

Status epilepticus

Palliative care

Anxiety

Diazoxide

Section

Medicines for hypoglycaemia

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

Dicloxacillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Didanosine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Diethylcarbamazine

Section

Antifilarials

- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

Lymphatic filariasis

Digitoxin

Section

Medicines used in heart failure

- Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
- Oral > Solid: 50 µg; 100 µg

Indications

Heart failure

Digoxin

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg

Medicines used in heart failure

- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg

Indications

Cardiac arrhythmia

Heart failure

Dihydroartemisinin + piperaquine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
- Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Dihydroergocryptine mesylate

Section

Medicines for central nervous system disorders

- Oral > Solid:

Indications

Parkinson disease

Diloxanide

Section

Antiamoebic and anti giardiasis medicines

- Oral > Solid: 500 mg (furoate)

Indications

Amoebiasis

Dimercaprol

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Dinoprostone (prostaglandin E2)

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 1 mg per mL

Indications

Therapeutic equivalent to alprostadil (prostaglandin E1) for

Other specified congenital anomaly of great arteries including arterial duct

Other specified congenital anomaly of great arteries including arterial duct

Diphtheria antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

Indications

Need for immunization against diphtheria alone

Diphtheria vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria alone

Diphtheria-pertussis-tetanus vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria-tetanus-pertussis, combined

Diphtheria-tetanus vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against combinations of infectious diseases

Docetaxel

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Unspecified malignant neoplasms of unspecified sites

Malignant neoplasms of prostate

Docusate sodium

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL
- Oral > Solid > capsule: 100 mg

Indications

Palliative care

Dolasetron

Section

Medicines for other common symptoms in palliative care

Therapeutic equivalent to [ondansetron](#) for

Palliative care

Antiemetic medicines

Therapeutic equivalent to [ondansetron](#) for

Nausea or vomiting

Dolutegravir

Section

Antiretrovirals > Integrase inhibitors

- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Donepezil

Section

Medicines for neurological disorders

- Oral > Liquid: 1 mg per mL (hydrochloride)
- Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)

Indications

Dementia due to Alzheimer disease

Dopamine

Section

Medicines used in heart failure

- Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)

Indications

Cardiogenic shock

Heart failure

Dostarlimab

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of corpus uteri

Doxorubicin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

Diffuse large B-cell lymphoma, not otherwise specified

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Rhabdomyosarcoma primary site

Osteosarcoma of bone or articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Follicular lymphoma

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Doxorubicin (as pegylated liposomal)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

Doxycycline

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)
- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

First choice

Cholera

Chlamydia trachomatis

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Cholera [children]

Chronic obstructive pulmonary disease with acute exacerbation

Other indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Dulaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Durvalumab

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

Other specified malignant neoplasms of bronchus or lung

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Therapeutic equivalent to [efavirenz](#) + [emtricitabine](#) + [tenofovir](#) for

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Eflornithine

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

Gambiense trypanosomiasis

Elbasvir + grazoprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

Eletriptan

Section

Medicines for acute migraine attacks

- Oral > Solid > tablet: 40 mg

Indications

Therapeutic equivalent to [sumatriptan](#) for

Migraine

Elxacaftor + tezacaftor + ivacaftor

Section

Medicines for cystic fibrosis

- Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg
- Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet

Indications

Cystic fibrosis

Emicizumab

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

Haemophilia A

Empagliflozin

Section

Hypoglycaemic agents

- Oral > Solid: 10 mg; 25 mg

Indications

Type 2 diabetes mellitus

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Contact with or exposure to human immunodeficiency virus

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Enalapril

Section

Antihypertensive medicines

- Oral > Liquid: 1 mg per mL (as hydrogen maleate)
- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Medicines used in heart failure

- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Indications

Essential hypertension

Heart failure

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Enoxaparin

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

Acute ischaemic heart disease

Venous thromboembolism

Entecavir

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

Enzalutamide

Section

Hormones and antihormones

- Oral > Solid: 40 mg

Indications

Therapeutic equivalent to [abiraterone](#) for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

Ephedrine

Section

Local anaesthetics

- Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

Indications

Cardiac complications of anaesthesia during labour or delivery

Epinephrine

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)	Chronic obstructive pulmonary disease Asthma
Antiallergics and medicines used in anaphylaxis Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)	Anaphylaxis
Antiarrhythmic medicines Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)	Cardiac arrest
Ophthalmological preparations > Mydriatics Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)	Primary open-angle glaucoma

Epoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin theta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Eptinezumab

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

Equine rabies immunoglobulin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

Indications

Rabies

Eravacycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Other carbapenem resistant Enterobacterales

Erenumab

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

Ergocalciferol

Section

Vitamins and minerals

- Oral > Liquid: 250 µg per mL (10 000 IU per mL)
- Oral > Solid: 1.25 mg (50 000 IU)

Indications

Therapeutic equivalent to [colecalfiferol](#) for

Calcium deficiency

Therapeutic equivalent to [colecalfiferol](#) for

Vitamin D deficiency

Calcium deficiency

Vitamin D deficiency

Ergometrine

Section

Uterotonics

- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

Postpartum haemorrhage

Erlotinib

Section

Targeted therapies

- Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Erythromycin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Ointment: 0.5%

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Chlamydial conjunctivitis

Gonococcal infection of eye

Erythropoiesis-stimulating agents

Section

Antianaemia medicines

- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

Anaemia due to chronic disease

Drug-induced aplastic anaemia

Escitalopram

Section

Medicines for anxiety disorders

Indications

Therapeutic equivalent to [fluoxetine](#) for

Generalised anxiety disorder

Estradiol

Section

Estrogens

- Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

Hypopituitarism

Gonadotropin deficiency

Turner syndrome

Estradiol cypionate + medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

Etanercept

Section

Immunomodulators for non-malignant disease

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Ethambutol

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Other specified tuberculosis

Tuberculosis

Ethambutol + isoniazid

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

Ethanol

Section

Antiseptics

- Local > Topical > Solution: 70% (denatured)

Indications

Denatured alcohol

Ether

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > solution:

Indications

Anaesthetics and therapeutic gases

Ethinylestradiol + etonogestrel

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section

Oral hormonal contraceptives

- Oral > Solid: 50 µg + 250 µg [4]
- Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives

- Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Ethionamide

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

Tuberculous meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

Ethosuximide

Section

Antiseizure medicines

- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg

Indications

Absence seizures, typical

Etonogestrel-releasing implant

Section

Implantable contraceptives

- Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

Etoposide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule

Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Germ cell tumour of testis

Osteosarcoma of bone or articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Malignant trophoblastic neoplasms of placenta

Retinoblastoma

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Everolimus

Section

Targeted therapies

- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

Indications

Other specified gliomas of brain

Exenatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Fentanyl

Section

Opioid analgesics

- Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
- Oral > Other: 200 to 1200 µg buccal film (as citrate)
- Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour

Indications

Other specified chronic cancer related pain

Chronic cancer pain

Ferrous salt

Section

Antianaemia medicines

- Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
- Oral > Solid > tablet: 60 to 65 mg elemental iron

Indications

Iron deficiency anaemia

Ferrous salt + folic acid

Section

Antianaemia medicines

- Oral > Solid: 60 mg iron + 2.8 mg
- Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

Indications

Iron deficiency anaemia

Iron deficiency anaemia

Spina bifida

Clefts of lip, alveolus or palate

Anencephaly or similar anomalies

Fexinidazole

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

Rhodesiense trypanosomiasis

Gambiense trypanosomiasis

Rhodesiense trypanosomiasis

Gambiense trypanosomiasis

Fexofenadine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to [loratadine](#) for

Allergic or hypersensitivity conditions of unspecified type

Fifth generation cephalosporins

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Filgrastim

Section

Immunomodulators

- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

Fingolimod

Section

Immunomodulators for non-malignant disease

- Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Flomoxef

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Flucloxacillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Fluconazole

Section

Antifungal medicines

- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg

Indications

Cryptococcosis

Candidosis

Flucytosine

Section

Antifungal medicines

- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule

Indications

Cryptococcosis

Fludarabine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fludrocortisone

Section

Adrenal hormones and synthetic substitutes

- Oral > Liquid: 100 µg per mL
- Oral > Solid > tablet: 100 µg (acetate)

Indications

Adrenocortical insufficiency

Fluorescein

Section

Diagnostic agents > Ophthalmic medicines

- Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

Indications

Fluorescein

Fluoride

Section

Dental medicines and preparations

- Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
- Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
- Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
- Local > Dental > Varnish: 22500 ppm fluoride (any type)

Indications

Dental caries

Fluorouracil

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Ointment: 5%

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per mL in vial
- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Indications

Plantar warts

Malignant neoplasms of nasopharynx

Malignant neoplasms of rectum

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of colon

Unspecified malignant neoplasms of unspecified sites

Fluoxetine

Section

Medicines for other common symptoms in palliative care

- Oral > Solid: 20 mg (as hydrochloride)

Medicines for depressive disorders

- Oral > Solid: 20 mg (as hydrochloride)

Medicines for anxiety disorders

- Oral > Solid: 20 mg (as hydrochloride)

Medicines for obsessive compulsive disorders

- Oral > Solid: 20 mg (as hydrochloride)

Indications

Palliative care

Depressive disorders

Generalised anxiety disorder

Social anxiety disorder

Panic disorder

Obsessive-compulsive disorder

Fluphenazine

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)

Indications

Schizophrenia or other primary psychotic disorders

Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for

Malignant neoplasms of prostate

Fluticasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

Fluticasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

Fluticasone furoate + vilanterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

Fluvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Fluvoxamine

Section

Medicines for anxiety disorders

Indications

Therapeutic equivalent to [fluoxetine](#) for

Generalised anxiety disorder

Folic acid

Section

Antianaemia medicines

- Oral > Solid: 400 µg
- Oral > Liquid: 1 mg per mL
- Oral > Solid: 1 mg tablet; 5 mg tablet

Indications

Cephalocele

Anencephaly or similar anomalies

Spina bifida

Folate deficiency anaemia

Fomepizole

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Fosfomycin (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section

Watch group antibiotics

- .

Indications

Other specified bacterial diseases

Fremanezumab

Section

Medicines for migraine prophylaxis

- Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe

Indications

Chronic migraine

Fresh-frozen plasma

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Fulvestrant

Section

Hormones and antihormones

- Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

Furosemide

Section

Diuretics

- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg

Medicines used in heart failure

- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg

Indications

Anuria or oliguria

Oedema

Heart failure

Gabapentin

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg

Indications

Neuropathic pain

Galcanezumab

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

Gallamine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)

Indications

Muscle relaxants

Gatifloxacin

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for

Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section

Access group antibiotics

Indications

First choice

Neonatal meningitis

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Sepsis without septic shock

Sepsis without septic shock

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Other specified prophylactic measures

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Other specified conjunctivitis

Infectious blepharitis

First choice

Neonatal meningitis

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Glass ionomer cement

Section

Dental medicines and preparations

- Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid

Indications

Dental caries

Glatiramer acetate

Section

Medicines for multiple sclerosis

- Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
- Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Glibenclamide

Section

Hypoglycaemic agents

- Oral > Solid: 5 mg; 2.5 mg

Indications

Type 2 diabetes mellitus

Gliclazide

Section

Hypoglycaemic agents

- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

Type 2 diabetes mellitus

Glucagon

Section

Medicines for hypoglycaemia

- Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

Indications

Hypoglycaemia in the context of diabetes

Glucose

Section

Solutions correcting water, electrolyte and acid-base disturbances

> Parenteral

- Parenteral > General injections > IV: 50% hypertonic
- Parenteral > General injections > IV: 5% isotonic; 10% hypertonic

Indications

Hypoglycaemia without associated diabetes

Other specified disorders of fluid, electrolyte or acid-base balance

Glucose + sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances

> Parenteral

- Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na⁺ 30 mmol/L and Cl⁻ 30 mmol/L; 5% + 0.9% (equivalent to Na⁺ 150 mmol/L and Cl⁻ 150 mmol/L); 5% + 0.45% (equivalent to Na⁺ 75 mmol/L and Cl⁻ 75 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Glutaral

Section

Disinfectants

- Local > Topical > Solution: 2%

Indications

Glutaral nonmedicinal

Glycerol

Section

Dermatological medicines > Moisturizers

- Local > Topical > Cream: 15 to 20%

Indications

Atopic eczema

Glyceryl trinitrate

Section

Antianginal medicines

- Oral > Solid: 500 µg sublingual tablet

Indications

Angina pectoris

Glycopyrronium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of prostate

Granisetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for

Palliative care

Antiemetic medicines

Therapeutic equivalent to [ondansetron](#) for

Nausea or vomiting

Griseofulvin

Section

Antifungal medicines

- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg

Indications

Dermatophytosis

Haemophilus influenzae type b vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Haloperidol

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 2 mg per mL ◦ Oral > Solid: 0.5 mg; 2 mg; 5 mg ◦ Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule	Palliative care
Medicines for psychotic disorders ◦ Parenteral > General injections > IM: 5 mg per mL in ampoule ◦ Oral > Solid: 2 mg; 5 mg	Schizophrenia or other primary psychotic disorders

Haloperidol decanoate

Section	Indications
Medicines for psychotic disorders	Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders

Halothane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation > liquid:	Anaesthetics and therapeutic gases

Heparin sodium

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial	Acute ischaemic heart disease Unstable angina Venous thromboembolism

Hepatitis A vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

Hepatitis B vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

Hepatitis E vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

Homatropine

Section

Ophthalmological preparations > Mydriatics

- Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

Indications

Anterior uveitis

Therapeutic equivalent to [atropine](#) for

Anterior uveitis

Human papilloma virus (HPV) vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Hydralazine

Section

Antihypertensive medicines

- Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
- Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Essential hypertension

Gestational hypertension

Hydrochlorothiazide

Section

Antihypertensive medicines

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg; 12.5 mg

Diuretics

- Oral > Solid > dosage form: 25 mg; 12.5 mg

Medicines used in heart failure

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg

Indications

Essential hypertension

Oedema

Heart failure

Hydrocortisone

Section	Indications
Hormones and antihormones Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of unspecified sites
Ophthalmological preparations > Anti-inflammatory agents Local > Ophthalmological > Ointment: 1% (acetate)	Scleritis Anterior uveitis
Antiallergics and medicines used in anaphylaxis Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)	Anaphylaxis
Anti-inflammatory medicines - Local > Rectal > Suppository: 25 mg (acetate) - Local > Rectal > Retention enema: 100 mg per 60 mL	Crohn disease site Ulcerative colitis
Dermatological medicines > Anti-inflammatory and antipruritic medicines - Local > Topical > Cream: 1% (acetate) - Local > Topical > Ointment: 1% (acetate)	Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus
Adrenal hormones and synthetic substitutes - Oral > Solid > tablet: 5 mg; 10 mg; 20 mg - Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule	Adrenocortical insufficiency

Hydromorphone

Section	Indications
Opioid analgesics	Therapeutic equivalent to morphine for Pain

Hydroxocobalamin

Section	Indications
Antianaemia medicines Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)	Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxychloroquine

Section

Antimalarial medicines > Medicines for chemoprevention

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 200 mg (as sulfate)

Indications

Therapeutic equivalent to [chloroquine](#) for

Malaria due to *Plasmodium falciparum*

Systemic lupus erythematosus

Cutaneous lupus erythematosus of unspecified type

Hydroxyurea (hydroxycarbamide)

Section

Cytotoxic medicines

- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies

Hyoscine butylbromide

Section

Medicines for other common symptoms in palliative care

- Parenteral > General injections > unspecified: 20 mg per mL injection

Indications

Palliative care

Hyoscine hydrobromide

Section

Medicines for other common symptoms in palliative care

- Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
- Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection

Indications

Palliative care

Hypochlorous acid

Section

Disinfectants

- Solution (aqueous): containing hypochlorous acid $\geq$ 150 parts per million

Antiseptics

- Solution (aqueous): containing hypochlorous acid $\geq$ 150 parts per million

Indications

Disinfectant, not elsewhere classified

Hypochlorite

Hypromellose

Section

Ophthalmological preparations

- Local > Ophthalmological > Solution (eye drops): 0.3%

Indications

Keratoconjunctivitis sicca

Ibrutinib

Section

Targeted therapies

- Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ibuprofen

Section

Medicines for acute migraine attacks

- Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 5 mg per mL

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg; 600 mg

Indications

Migraine

Patent arterial duct

Pain

Idoxuridine

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 0.1%
- Local > Ophthalmological > Ointment: 0.2%

Indications

Herpes simplex keratitis

Ifosfamide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Rhabdomyosarcoma primary site

Osteosarcoma of bone or articular cartilage of unspecified sites

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of unspecified sites

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Imatinib

Section

Targeted therapies

- Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Chronic myeloid leukaemia, not elsewhere classified

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Imipenem + cilastatin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Antituberculosis medicines

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for

[Peritoneal abscess \(severe\)](#)

Therapeutic equivalent to [meropenem](#) for

[Neutropaenia \(high-risk\)](#)

Therapeutic equivalent to [meropenem](#) for

[Peritonitis \(severe\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

[Antibiotic resistant Acinetobacter baumannii](#)

Therapeutic equivalent to [meropenem](#) for

[Multi-drug resistant Mycobacterium tuberculosis](#)

Imipenem + cilastatin + relebactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

[Carbapenem-resistant Pseudomonas aeruginosa](#)

[Other carbapenem resistant Enterobacterales](#)

Indapamide

Section

Antihypertensive medicines

Therapeutic equivalent to [hydrochlorothiazide](#) for

[Essential hypertension](#)

Medicines used in heart failure

Therapeutic equivalent to [hydrochlorothiazide](#) for

[Heart failure](#)

Indinavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Indometacin

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to [ibuprofen](#) for

Patent arterial duct

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Influenza vaccine (seasonal)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against influenza

Insulin (analogue, long-acting)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin (analogue, rapid-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen	Type 1 diabetes mellitus Type 2 diabetes mellitus

Insulin (human, intermediate-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (human, short-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin analogues

Section	Indications
Insulins Not specified	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin aspart

Section	Indications
Insulins - Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen - Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus

Insulin degludec

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

Insulin detemir

Section

Insulins

Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

Insulin glargine

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

Insulin glulisine

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Insulin lispro

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Intraperitoneal dialysis solution

Section

Peritoneal dialysis solution

- Solution: of appropriate composition in accordance with local clinical guidelines.

Indications

Care involving peritoneal dialysis

Iodine

Section

Antiseptics

Therapeutic equivalent to [povidone iodine](#) for

Povidone iodine

Vitamins and minerals

- Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)

Iodine deficiency

Iodine + potassium iodide (Lugol's solution)

Section

Thyroid hormones and antithyroid medicines

- Oral > Liquid: 5% w/v + 10% w/v (aqueous)

Indications

Thyrotoxicosis

Iohexol

Section

Diagnostic agents > Radiocontrast media

- Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

Indications

X-ray contrast media, iodinated

Ipecacuanha

Section

Antidotes and other substances used in poisonings > Non-specific

- Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

Indications

Unspecified injury, poisoning or certain other consequences of external causes

Ipilimumab

Section

Immunomodulators

- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Ipratropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler

Indications

Chronic obstructive pulmonary disease

Asthma

Irinotecan

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Rhabdomyosarcoma primary site

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Isoflurane

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Isoniazid

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

Other specified tuberculosis

Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections

- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

Isoniazid + rifampicin

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

Tuberculosis

Isoniazid + rifapentine

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

Latent tuberculosis

Isoprenaline

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
- Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

Indications

Bradycardia

Cardiogenic shock

Isosorbide dinitrate

Section

Antianginal medicines

- Oral > Solid: 5 mg sublingual tablet

Indications

Angina pectoris

Itraconazole

Section

Antifungal medicines

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg

Indications

Chronic pulmonary aspergillosis

Paracoccidioidomycosis

Sporotrichosis

Histoplasmosis

Talaromycosis

Chromoblastomycosis

Ivacaftor

Section

Medicines for cystic fibrosis

- Oral > Solid > tablet: 75 mg; 150 mg
- Oral > Solid > granules: 59.5 mg; 75 mg

Indications

Cystic fibrosis

Ivermectin

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 3 mg

Antifilarials

- Oral > Solid > tablet: 3 mg

Medicines for ectoparasitic infections

- Oral > Solid > tablet: 3 mg

Indications

Hookworm diseases

Strongyloidiasis

Trichuriasis

Ancylostomiasis

Ascariasis

Lymphatic filariasis

Onchocerciasis

Scabies

Kanamycin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

Kanamycin (injection)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Ketamine

Section

General anaesthetics and oxygen > Injectable medicines

- Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)

Indications

Anaesthetics and therapeutic gases

Ketoconazole

Section

Medicines for endocrine disorders

- Oral > Solid > tablet: 200 mg

Indications

Cushing syndrome

Lactulose

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid

Indications

Palliative care

Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to emtricitabine + tenofovir for

Contact with or exposure to human immunodeficiency virus

Therapeutic equivalent to emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamotrigine

Section	Indications
Antiseizure medicines Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)	Epilepsy or seizures

Latanoprost

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops	Primary open-angle glaucoma

Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	Plasma cell myeloma

Lenvatinib

Section	Indications
Targeted therapies Oral > Solid > capsule: 4 mg; 10 mg	Renal cell carcinoma of kidney, except renal pelvis

Letrozole

Section	Indications
Ovulation inducers Oral > Solid > dosage form: 2.5 mg	Female infertility without specification whether primary or secondary

Leuprorelin

Section	Indications
Hormones and antihormones Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe	Malignant neoplasms of breast Malignant neoplasms of prostate

Levamisole

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

Ascariasis

Levetiracetam

Section

Antiseizure medicines

- Oral > Liquid: 100 mg per mL
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
- Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

Indications

Epilepsy or seizures

Status epilepticus

Levodopa

Section

Medicines for parkinsonism

- Oral > Solid: 250 mg

Indications

Parkinson disease

Levodopa + benserazide

Section

Medicines for parkinsonism

Indications

Therapeutic equivalent to **levodopa + carbidopa** for

Parkinson disease

Levodopa + carbidopa

Section

Medicines for parkinsonism

- Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications

Parkinson disease

Levofloxacin

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Levonorgestrel

Section

Oral hormonal contraceptives

- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg

Intrauterine devices

- Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section

Implantable contraceptives

- Implant > Subdermal: 75 mg per rod (two-rods)

Indications

Contact with health services for insertion of contraceptive device

Levothyroxine

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

Indications

Hypothyroidism

Lidocaine

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)

Local anaesthetics

- Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride)
- Local > Topical > unspecified: 2 to 4% (hydrochloride)

Indications

Ventricular tachyarrhythmia

Local anaesthetics

Lidocaine + epinephrine

Section

Local anaesthetics

- Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine
- Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine

Indications

Local anaesthetics

Lindane

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Cream: 1%
- Local > Topical > Lotion: 1%

Indications

Scabies

Linezolid

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Multi-drug resistant *Mycobacterium tuberculosis*

Liraglutide

Section

Medicines for endocrine disorders

- Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Hypoglycaemic agents

Indications

Obesity

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Lisinopril + amlodipine

Section

Antihypertensive medicines

- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

Essential hypertension

Lisinopril + hydrochlorothiazide

Section

Antihypertensive medicines

- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

Essential hypertension

Lisocabtagene maraleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for

Diffuse large B-cell lymphomas

Lithium carbonate

Section

Medicines for bipolar disorders

- Oral > Solid: 300 mg

Indications

Bipolar or related disorders

Loperamide

Section

Medicines for other common symptoms in palliative care

- Oral > Solid > dosage form: 2 mg

Indications

Palliative care

Lopinavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Loratadine

Section

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 1 mg per mL
- Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)

Indications

Allergic or hypersensitivity conditions of unspecified type

Lorazepam

Section

Antiseizure medicines

- Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule

Medicines for anxiety disorders

Indications

Status epilepticus

Therapeutic equivalent to [diazepam](#) for

Anxiety

Losartan

Section

Antihypertensive medicines

- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Medicines used in heart failure

- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Indications

Essential hypertension

Heart failure

Lovastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Magnesium sulfate

Section

Antiseizure medicines

- Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
- Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)

Indications

Severe pre-eclampsia

Eclampsia

Malaria vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain specified single infectious diseases

Mannitol

Section

Diuretics

- Parenteral > General injections > IV: 10% solution; 20% solution

Indications

Ocular hypertension

Cerebral oedema

Measles vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against measles alone

Mebendazole

Section	Indications
Intestinal anthelminthics Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Hookworm diseases Trichuriasis Ascariasis Enterobiasis
Cysticidal medicines Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Other specified echinococcosis

Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives - Parenteral > General injections > IM: 150 mg per mL in 1 mL vial - Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction
Progestogens Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

Mefloquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > Medicines for chemoprophylaxis in travellers Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)	Malaria due to Plasmodium falciparum
Antimalarial medicines > Medicines for chemoprevention Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Meglumine iotroxate

Section

Diagnostic agents > Radiocontrast media

- Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL

Indications

X-ray contrast media, iodinated

Melarsoprol

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

Gambiense trypanosomiasis

Rhodesiense trypanosomiasis

Melphalan

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Meningococcal meningitis vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Mercaptopurine

Section

Cytotoxic medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 50 mg tablet

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Langerhans cell histiocytosis

Unspecified malignant neoplasms of unspecified sites

Meropenem

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Medicines for bacterial central nervous system infections

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neonatal meningitis

Peritoneal abscess (severe)

Neutropaenia (high-risk)

Peritonitis (severe)

Second choice

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant *Acinetobacter baumannii*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Mesalazine

Section

Anti-inflammatory medicines

Indications

Therapeutic equivalent to **sulfasalazine** for

Crohn disease site

Therapeutic equivalent to **sulfasalazine** for

Ulcerative colitis

Mesna

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg

Indications

Rhabdomyosarcoma primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Osteosarcoma of bone or articular cartilage of unspecified sites

Unspecified malignant neoplasms of unspecified sites

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Burkitt lymphoma including Burkitt leukaemia

Metformin

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg (hydrochloride)

Indications

Type 2 diabetes mellitus

Methadone

Section

Medicines for opioid use disorders

- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Opioid analgesics

- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
- Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

Indications

Opioid dependence

Chronic cancer pain

Methimazole

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 5 mg; 10 mg

Indications

Thyrotoxicosis

Methionine

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: 250 mg (DL)

Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Methotrexate

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Medicines for juvenile joint diseases

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Osteosarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of breast

Unspecified malignant neoplasms of unspecified sites

Malignant trophoblastic neoplasms of placenta

Psoriasis of unspecified type

Rheumatoid arthritis, serology unspecified

Crohn disease site

Psoriatic arthritis

Juvenile idiopathic arthritis

Methoxy polyethylene glycol-epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Methyldopa

Section

Antihypertensive medicines

- Oral > Solid: 250 mg

Indications

Essential hypertension

Gestational hypertension

Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to [ergometrine](#) for

Postpartum haemorrhage

Methylphenidate

Section

Medicines for mental and behavioural disorders

- Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)
- Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)

Indications

Attention deficit hyperactivity disorder

Methylprednisolone

Section

Hormones and antihormones

- Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
- Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Methylthioninium chloride

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

Indications

Acquired methaemoglobinaemia

Meticillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Metoclopramide

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Antiemetic medicines

- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (scored) (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Palliative care

Nausea or vomiting

Metoprolol

Section

Antianginal medicines

Antihypertensive medicines

Antiarrhythmic medicines

Medicines used in heart failure

Indications

Therapeutic equivalent to [bisoprolol](#) for

Angina pectoris

Therapeutic equivalent to [bisoprolol](#) for

Essential hypertension

Therapeutic equivalent to [bisoprolol](#) for

Cardiac arrhythmia

Therapeutic equivalent to [bisoprolol](#) for

Heart failure

Metronidazole

Section

Antiamoebic and anti giardiasis medicines

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection

Indications

Amoebiasis

First choice

Trichomoniasis

Intestinal infections due to *Clostridioides difficile*

Necrotising fasciitis

co-prescribed with cefazolin

Other specified prophylactic measures

co-prescribed with cefotaxime

Peritoneal abscess (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (severe)

co-prescribed with cefotaxime

Peritonitis (mild-moderate)

co-prescribed with cefotaxime

Peritonitis (severe)

co-prescribed with ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescribed with ceftriaxone

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Peritonitis (mild-moderate)

co-prescribed with ceftriaxone

Peritonitis (severe)

Second choice

co-prescribed with ciprofloxacin

Peritoneal abscess (mild-moderate)

co-prescribed with ciprofloxacin

Peritonitis (mild-moderate)

Bacterial infection of unspecified site

Micafungin

Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

Systemic or invasive candidosis

Miconazole

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Cream: 2% (nitrate)
- Local > Topical > Ointment: 2% (nitrate)

Indications

Fungal infection of the skin

Midazolam

Section	Indications
Antiseizure medicines ◦ Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration) ◦ Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)	Therapeutic equivalent to lorazepam for - Status epilepticus - Status epilepticus
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 2 mg per mL ◦ Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial ◦ Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ◦ Oral > Solid > dosage form: 7.5 mg; 15 mg	Palliative care
Preoperative medication and sedation for short-term procedures ◦ Parenteral > General injections > IV: 1 mg per mL in 5 vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial ◦ Oral > Liquid: 2 mg per mL ◦ Oral > Solid > dosage form: 15 mg; 7.5 mg	Sedative-hypnotic and anxiolytic drugs

Mifepristone - misoprostol

Section	Indications
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package	- Unspecified time of fetal death, cause not specified - Induced abortion

Miltefosine

Section

Antileishmaniasis medicines

- Oral > Solid: 10 mg; 50 mg

Indications

Visceral leishmaniasis

Cutaneous leishmaniasis

Mucocutaneous leishmaniasis

Misoprostol

Section

Uterotonics

- Local > Vaginal > tablet: 25 µg
- Oral > Solid: 200 µg

Medicines for medical abortion

- Oral > Solid > tablet: 200 µg

Indications

Unspecified obstetric condition

Postpartum haemorrhage

Spontaneous abortion, incomplete, without complication

Mometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

Mometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

Morphine

Section	Indications
Opioid analgesics ◦ Oral > Liquid: 5 mg per 5 mL (morphine hydrochloride or morphine sulfate); 10 mg per 5 mL (morphine hydrochloride or morphine sulfate) ◦ Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate) ◦ Oral > Solid > tablet: 10 mg immediate release (morphine sulfate) ◦ Oral > Solid > dosage form: 30 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 5 mg slow-release (morphine hydrochloride or morphine sulfate) ◦ Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)	Pain
Preoperative medication and sedation for short-term procedures ◦ Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)	Opioids or related analgesics and agents affecting opioid receptors

Moxidectin

Section	Indications
Antifilarials ◦ Oral > Solid > tablet: 2 mg	Therapeutic equivalent to ivermectin for Lymphatic filariasis Therapeutic equivalent to ivermectin for Onchocerciasis

Moxifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 400 mg	Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

Mpox vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Multiple micronutrient powder

Section

Vitamins and minerals

- Sachets containing:
 - - iron (elemental) 12.5 mg (as coated ferrous fumarate)
 - - zinc (elemental) 5 mg
 - - vitamin A 300 micrograms
 - - with or without other micronutrients at recommended daily values

Indications

Iron deficiency anaemia

Multiple micronutrient supplement

Section

Other medicines administered to the mother

- Tablet containing:
 - Vit A: 800 mcg retinol activity equivalent
 - Vit C: 70 mg
 - Vit D: 5 mcg (200 IU)
 - Vit E: 10 mg alpha tocopherol equivalent
 - Vit B1: 1.4 mg
 - Vit B2: 1.4 mg
 - Vit B3: 18 mg niacin equivalent
 - Vit B6: 1.9 mg
 - Folic acid: 400 mcg
 - Vit B12: 2.6 mcg
 - Iron: 30 mg
 - Iodine: 150 mcg
 - Zinc: 15 mg
 - Selenium: 65 mcg
 - Copper: 2 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy

Mumps vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against mumps alone

Mupirocin

Section

Dermatological medicines > Anti-infective medicines

- Local > Topical > Cream: 2% (as mupirocin calcium)
- Local > Topical > Ointment: 2%

Indications

Superficial bacterial folliculitis

Impetigo

Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for

Acute ischaemic heart disease

Therapeutic equivalent to [enoxaparin](#) for

Venous thromboembolism

Nafcillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Nalidixic acid

Section

Anti-infective medicines

- Oral > Solid: 250 mg; 500 mg

Indications

Shigella resistant to unspecified antibiotic

Naloxone

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)

Indications

Unintentional exposure to or harmful effects of opioids or related analgesics

Naltrexone

Section

Medicines for alcohol use disorders

- Parenteral > General injections > IM: 380 mg in vial (extended-release)
- Oral > Solid > tablet: 50 mg

Indications

Disorders due to use of alcohol

Naproxen

Section

Medicines for acute migraine attacks

Indications

Therapeutic equivalent to [ibuprofen](#) for

Migraine

Natamycin

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Suspension: 5% eye drops

Indications

Infectious keratitis

Nelfinavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 250 mg (as mesilate)
- Oral > Other: 50 mg per g oral powder

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Neostigmine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Medicines for myasthenia gravis

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

Anticholinesterase reversible

Myasthenia gravis

Myasthenia gravis

Netilmicin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

Nevirapine

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Niclosamide

Section

Intestinal anthelmintics

- Oral > Solid: 500 mg tablet (chewable)

Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Nicotinamide

Section

Vitamins and minerals

- Oral > Solid: 50 mg

Indications

Pellagra

Nicotine replacement therapy

Section

Medicines for nicotine use disorders

- Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
- Oral > Solid > lozenge: 2 mg; 4 mg lozenge
- Local > Buccal > Oral spray: 1 mg per actuation
- Local > Buccal > Chewing gum: 2 mg; 4 mg

Indications

Nicotine dependence

Nifedipine

Section

Antioxytotics (tocolytics)

- Oral > Solid: 10 mg (immediate-release)

Antianginal medicines

- Oral > Solid: 10 mg

Antihypertensive medicines

- Oral > Solid: 10 mg tablet; sustained-release formulations

Indications

Preterm labour without delivery

Angina pectoris

Essential hypertension

Nifurtimox

Section

American trypanosomiasis

- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

Chagas disease

Gambiense trypanosomiasis

Nilotinib

Section

Targeted therapies

- Oral > Solid > capsule: 150 mg; 200 mg

Indications

Chronic myelogenous leukaemia, BCR-ABL1-positive

Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for

Malignant neoplasms of prostate

Nitrofurantoin

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

Infectious cystitis

Nitrous oxide

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

Nivolumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion ◦ Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion ◦ Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion	Therapeutic equivalent to pembrolizumab for - Melanoma of skin - Melanoma of skin - Renal cell carcinoma of kidney, except renal pelvis - Squamous cell carcinoma of oesophagus - Adenocarcinoma of oesophagogastric junction - Adenocarcinoma of stomach - Other specified malignant neoplasms of bronchus or lung

Norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 350 µg	Contact with health services for contraceptive management
Progestogens ◦ Oral > Solid: 5 mg	- Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for - Excessive menstruation with irregular cycle

Norethisterone enantate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution	Contact with health services for reasons associated with reproduction

Normal immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 5% protein solution; 10% protein solution ◦ Parenteral > General injections > IM: 16% protein solution ◦ Parenteral > General injections > SC: 15% protein solution; 16% protein solution	- Primary immunodeficiencies - Mucocutaneous lymph node syndrome - Langerhans cell histiocytosis
Medicines for Guillain-Barré syndrome ◦ Parenteral > General injections > IV: 5% protein solution; 10% protein solution	Acute inflammatory demyelinating polyneuropathy

Nystatin

Section

Antifungal medicines

- Oral > Liquid: 100000 IU per mL
- Local > Topical > Other: 100000 IU pessary
- Oral > Solid > dosage form: 500000 IU
- Oral > Solid > lozenge: 100000 IU

Indications

Candidosis

Ocrelizumab

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
- Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

Octreotide

Section

Medicines for disorders of the pituitary hormone system

- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

Indications

Acromegaly or pituitary gigantism

Ofloxacin

Section

Ear, nose and throat medicines [c]

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 0.3%

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

Therapeutic equivalent to ciprofloxacin for

Infectious diseases of external ear

Other specified conjunctivitis

Infectious keratitis

Multi-drug resistant Mycobacterium tuberculosis

Olanzapine

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 10 mg in vial powder for injection

Indications

Therapeutic equivalent to [risperidone](#) for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Omadacycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

Omeprazole

Section

Antiulcer medicines

- Parenteral > General injections > IV: 40 mg in vial
- Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid
- Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg

Indications

Gastrointestinal bleeding

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Ondansetron

Section

Medicines for other common symptoms in palliative care

- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)
- Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
- Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)

Antiemetic medicines

- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule
- Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
- Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)

Indications

Palliative care

Nausea or vomiting

Oral rehydration salts

Section

Solutions correcting water, electrolyte and acid-base disturbances

> Oral

- Powder for dilution in 200 mL, 500 mL, 1 L:
-
- - glucose 75 mEq or mmol/L
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mEq or mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L

Oral rehydration

- Powder for dilution in 200 mL, 500 mL, 1 L:
-
- - glucose 75 mEq or mmol/L
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mEq or mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Diarrhoea

Oral rehydration salts - zinc sulfate

Section

Medicines used in diarrhoea

- Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)

Indications

Diarrhoea

Oseltamivir

Section

Other antivirals

- Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

Influenza due to identified seasonal influenza virus

Osimertinib

Section

Targeted therapies

- Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Oxacillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Oxaliplatin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Oxamniquine

Section

Antischistosomes and other antitrepatode medicines

- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid > capsule: 250 mg

Indications

Schistosomiasis due to *Schistosoma mansoni*

Oxazolindinones

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Oxycodone

Section

Opioid analgesics

Indications

Therapeutic equivalent to [morphine](#) for

Pain

Oxygen

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation: (medical gas)

Medical gases

- Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

Respiratory failure as acute or chronic

Oxytetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [tetracycline](#) for

Other specified conjunctivitis

Therapeutic equivalent to [tetracycline](#) for

Infectious keratitis

Therapeutic equivalent to [tetracycline](#) for

Infectious blepharitis

Therapeutic equivalent to [tetracycline](#) for

Trachoma

Oxytocin

Section

Uterotonics

- Parenteral > General injections > unspecified: 10 IU per mL

Indications

Postpartum haemorrhage

P-aminosalicylate sodium

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

P-aminosalicylic acid

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Paclitaxel

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 6 mg per mL

Indications

Malignant neoplasms of cervix uteri

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of the ovary

Malignant neoplasms of nasopharynx

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Palbociclib

Section

Targeted therapies

- Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Paliperidone

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

Indications

Therapeutic equivalent to [risperidone](#) for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Palonosetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for

Palliative care

Antiemetic medicines

Therapeutic equivalent to [ondansetron](#) for

Nausea or vomiting

Pancreatic enzymes

Section	Indications
Gastrointestinal medicines ◦ Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units. ◦ *Units expressed in Ph. Eur	Enzyme intestinal
Medicines for cystic fibrosis ◦ Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units. ◦ *Units expressed in Ph. Eur	Cystic fibrosis

Panitumumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial	Other specified malignant neoplasms of large intestine

Paracetamol (acetaminophen)

Section	Indications
Medicines for acute migraine attacks ◦ Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL ◦ Local > Rectal > Suppository: 250 mg ◦ Oral > Solid > dispersible tablet: 100 mg; 250 mg ◦ Oral > Solid > tablet: 250 mg; 325 mg; 500 mg	Migraine
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) ◦ Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL ◦ Local > Rectal > Suppository: 100 mg; 250 mg ◦ Oral > Solid > dispersible tablet: 100 mg; 250 mg ◦ Oral > Solid > tablet: 250 mg; 325 mg; 500 mg	Pain

Paromomycin

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)	Visceral leishmaniasis
Antiamoebic and anti giardiasis medicines ◦ Oral > Liquid: 125 mg per 5 mL as sulfate ◦ Oral > Solid: 250 mg as sulfate	Amoebiasis

Paroxetine

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to fluoxetine for Generalised anxiety disorder

Pegaspargase

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section	Indications
Immunomodulators ◦ Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe	Acquired neutropaenia

Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

Pembrolizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection	Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Adenocarcinoma of stomach Malignant neoplasms of oesophagogastric junction Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Therapeutic equivalent to nivolumab for Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung

Penicillamine

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Oral > Solid: 250 mg	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid: 250 mg	Rheumatoid arthritis, serology unspecified

Pentamidine

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)	Visceral leishmaniasis
Medicines for the treatment of 1st stage African trypanosomiasis ◦ Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection	Gambiense trypanosomiasis
Antipneumocystosis and antitoxoplasmosis medicines ◦ Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)	Pneumocystosis

Perindopril + amlodipine + indapamide

Section	Indications
Antihypertensive medicines ◦ Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg	Essential hypertension

Permethrin

Section	Indications
Dermatological medicines > Scabicides and pediculicides ◦ Local > Topical > Lotion: 1% ◦ Local > Topical > Cream: 5%	Pediculosis corporis Pediculosis capitis Scabies

Pertussis vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against pertussis alone

Pertuzumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Phenelzine

Section	Indications
Medicines for depressive disorders ◦ Oral > Solid > dosage form: 15 mg (as sulfate)	Other specified depressive disorders

Phenobarbital

Section

Antiseizure medicines

- Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
- Oral > Liquid: 15 mg per 5 mL
- Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg

Indications

Status epilepticus

Epilepsy or seizures

Phenoxymethylpenicillin

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
- Oral > Solid: 250 mg (as potassium salt) tablet

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Periapical abscess without sinus

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Phenytoin

Section

Antiseizure medicines

- Oral > Liquid: 30 mg per 5 mL (phenytoin)
- Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
- Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
- Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)

Indications

Epilepsy or seizures

Phosphorus

Section

Medicines for endocrine disorders

- Oral > Other: 500 mg in sachet (elemental phosphorus) granules
- Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

Hypophosphataemic rickets

Phytomenadione

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution; 1 mg per 0.5 mL in ampoule
- Oral > Solid > tablet: 5 mg tablet

Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Haemorrhagic or haematological disorders of fetus or newborn

Pilocarpine

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

Indications

Acute angle closure with pupillary block

Ocular hypertension

Primary open-angle glaucoma

Piperacillin + tazobactam

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropaenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

Platelets

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Plazomicin

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Escherichia coli*

Carbapenem resistant *Klebsiella pneumoniae*

Pneumococcal vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Podophyllotoxin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [podophyllum resin](#) for

Plantar warts

Therapeutic equivalent to [podophyllum resin](#) for

Anogenital warts

Podophyllum resin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 10 to 25%

Indications

Plantar warts

Anogenital warts

Poliomyelitis vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against poliomyelitis

Polygeline

Section

Plasma substitutes

- Parenteral > General injections > IV: 3.5% injectable solution
- Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to [dextran 70](#) for

Hypovolaemia

Hypovolaemia

Polymyxin B (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant *Acinetobacter baumannii*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Polymyxins

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Porcatant alfa

Section

Medicines administered to the neonate [c]

- Respiratory > Suspension: 80 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

Potassium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

- Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K⁺ 1.5 mmol/mL and Cl⁻ 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K⁺ 1 mmol/mL and Cl⁻ 2 mmol/mL); 15% solution for dilution (equivalent to K⁺ 2 mmol/mL and Cl⁻ 2 mmol/mL)

Solutions correcting water, electrolyte and acid-base disturbances > Oral

- Oral > Liquid: powder for solution

Indications

Hypokalaemia

Hypokalaemia

Potassium ferric hexacyanoferrate (Prussian blue)

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: Powder for oral administration

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Potassium iodide

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 65 mg (scored)

Antifungal medicines

- Local > Topical > Solution: Saturated solution

Indications

Thyrotoxicosis

Sporotrichosis

Potassium permanganate

Section

Dermatological medicines > Anti-infective medicines

- Local > Topical > Solution: aqueous solution: 1:10 000

Indications

Tropical phagedaenic ulcer

Pemphigus

Other specified pyogenic bacterial infection of skin or subcutaneous tissue

Impetigo

Povidone iodine

Section

Antiseptics

- Local > Topical > Solution: 10% (equivalent to 1% available iodine)

Indications

Povidone iodine

Pralidoxime

Section

Antidotes and other substances used in poisonings > Specific

- .

Indications

Exposure to or harmful effects of undetermined intent of pesticides

Pramipexole

Section

Medicines for central nervous system disorders

- Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

Indications

Parkinson disease

Pravastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Praziquantel

Section

Cysticidal medicines

- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Antischistosomes and other antitremitode medicines

- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Intestinal anthelmintics

- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

Cysticercosis of central nervous system

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Hymenolepiasis

Taeniasis due to *Taenia solium*

Precipitated sulfur

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Ointment:

Indications

Therapeutic equivalent to [benzyl benzoate](#) for

Pediculosis corporis

Therapeutic equivalent to [benzyl benzoate](#) for

Pediculosis capitis

Therapeutic equivalent to [benzyl benzoate](#) for

Pthiriasis

Therapeutic equivalent to [benzyl benzoate](#) for

Scabies

Prednisolone

Section

Anti-inflammatory medicines

- Local > Rectal > Retention enema:
- Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

Hormones and antihormones

- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg

Ophthalmological preparations > Anti-inflammatory agents

- Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

Medicines for cluster headache

- Oral > Solid > tablet: 5 mg; 25 mg

Antiseizure medicines

- Oral > Liquid: 1 mg per mL
- Oral > Solid > tablet: 1 mg; 5 mg; 10 mg

Indications

Therapeutic equivalent to [hydrocortisone](#) for

Crohn disease site

Crohn disease site

Ulcerative colitis

Lymphoid leukaemia, not elsewhere classified

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Malignant neoplasms of prostate

Follicular lymphoma

Allergic or hypersensitivity conditions of unspecified type

Scleritis

Anterior uveitis

Adrenocortical insufficiency

Trigeminal autonomic cephalalgias

Infantile spasms

Prednisone

Section	Indications
Hormones and antihormones	Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Follicular lymphoma
Antiallergics and medicines used in anaphylaxis	Therapeutic equivalent to prednisolone for Allergic or hypersensitivity conditions of unspecified type
Adrenal hormones and synthetic substitutes Oral > Solid > tablet: 1 mg	Therapeutic equivalent to prednisolone for Adrenocortical insufficiency

Pretomanid

Section	Indications
Antituberculosis medicines Oral > Solid > tablet: 200 mg	Multi-drug resistant Mycobacterium tuberculosis

Primaquine

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)

Indications

Malaria due to Plasmodium ovale

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Probenecid

Section

Medicines used to treat gout

- Oral > Solid: 500 mg

Indications

Gout

Procainamide

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)
- Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

Indications

Cardiac arrhythmia

Procaine benzylpenicillin

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

Congenital syphilis [children]

Second choice

Syphilis

Procarbazine

Section

Cytotoxic medicines

- Oral > Solid: 50 mg (as hydrochloride)
- Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Progesterone vaginal ring

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

Proguanil

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg tablet (hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Promethazine

Section

Antiemetic medicines

- Oral > Liquid: 5 mg per 5 mL (hydrochloride)
- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule

Indications

Nausea or vomiting

Propanol

Section

Antiseptics

Indications

Therapeutic equivalent to [ethanol](#) for

Denatured alcohol

Propofol

Section

General anaesthetics and oxygen > Injectable medicines

- Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL

Indications

Anaesthetics and therapeutic gases

Propranolol

Section

Antianginal medicines

- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
- Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antihypertensive medicines

- Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Medicines for migraine prophylaxis

- Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)

Antiarrhythmic medicines

- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
- Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Indications

Angina pectoris

Essential hypertension

Migraine

Cardiac arrhythmia

Propylthiouracil

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 mg

Indications

Thyrotoxicosis

Protamine sulfate

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Protionamide

Section

Antituberculosis medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

Therapeutic equivalent to ethionamide for

Multi-drug resistant Mycobacterium tuberculosis

Pyrantel

Section

Intestinal anthelminthics

- Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

Hookworm diseases

Trichuriasis

Ascariasis

Enterobiasis

Pyrazinamide

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

Tuberculosis

Pyridostigmine

Section	Indications
Medicines for myasthenia gravis ◦ Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide) ◦ Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)	Myasthenia gravis
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide) ◦ Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)	Myasthenia gravis

Pyridoxine

Section	Indications
Vitamins and minerals ◦ Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)	Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia

Pyrimethamine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines ◦ Oral > Solid: 25 mg	Toxoplasmosis

Quetiapine

Section	Indications
Medicines for psychotic disorders	Therapeutic equivalent to risperidone for
	Schizophrenia or other primary psychotic disorders
Medicines for bipolar disorders ◦ Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)	Bipolar or related disorders

Quinidine

Section	Indications
Antiarrhythmic medicines ◦ Oral > Solid: 200 mg (sulfate)	Cardiac arrhythmia

Quinine

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion

Indications

Malaria due to Plasmodium falciparum

Rabies vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rabies

Raltegravir

Section

Antiretrovirals > Integrase inhibitors

- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Ranibizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- .

Indications

Retinal venous occlusions

Diabetic macular oedema

Degenerative high myopia

Age-related macular degeneration

Ranitidine

Section

Antiulcer medicines

- Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Rasburicase

Section

Supportive medicines

- Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

Tumour lysis syndrome

Ravidasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

Chronic hepatitis C

Ready to use therapeutic food

Section

Therapeutic foods

- Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.

Indications

Acute malnutrition in infants, children or adolescents

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Red blood cells

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Resin-based composite (high-viscosity)

Section

Dental medicines and preparations

- Local > Topical > Other: Single-use capsule or multi-use syringe

Indications

Dental caries

Resin-based composite (low-viscosity)

Section

Dental medicines and preparations

- Local > Topical > Other: Single-use applicator or multi-use bottle

Indications

Dental caries

Respiratory syncytial virus vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Retinol

Section	Indications
Vitamins and minerals ◦ Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate) ◦ Oral > Liquid: 100000 IU per mL (as palmitate or acetate) ◦ Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule	Vitamin A deficiency

Ribavirin

Section	Indications
Other antivirals ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Viral haemorrhagic fever, not elsewhere classified
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

Ribociclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Riboflavin

Section	Indications
Vitamins and minerals ◦ Oral > Solid: 5 mg	Vitamin B2 deficiency

Rifabutin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 600 mg in vial powder for injection
- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Indications

Other specified tuberculosis

Tuberculosis

Leprosy

Rifapentine

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 150 mg; 300 mg

Indications

Latent tuberculosis

Tuberculosis

Risdiplam

Section

Medicines for neurological disorders

- Oral > Liquid: 0.75 mg per mL powder for oral liquid
- Oral > Solid > dispersible tablet: 5 mg

Indications

Spinal muscular atrophy

Risperidone

Section

Medicines for psychotic disorders

- Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
- Parenteral > General injections > IM:

Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to [paliperidone](#) for

Schizophrenia or other primary psychotic disorders

Ritonavir

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Rituximab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma
Medicines for multiple sclerosis Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial	Multiple sclerosis

Rivaroxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Other specified atrial fibrillation Therapeutic equivalent to dabigatran for Venous thromboembolism

Ropinirole

Section	Indications
Medicines for central nervous system disorders Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 mg immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release	Parkinson disease

Rotavirus vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Rubella vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against rubella alone

Salbutamol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease - Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate) - Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers	Chronic obstructive pulmonary disease Asthma

Salicylic acid

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Solution: 5%	Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses

Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 200 mg; 500 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Selenium sulfide

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Suspension: 2% detergent-based	Seborrhoeic dermatitis Pityriasis versicolor

Semaglutide

Section	Indications
Hypoglycaemic agents - Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution - Oral > Solid > tablet: 3 mg - Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL	Obesity Type 2 diabetes mellitus

Senna

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 7.5 mg per 5 mL oral liquid

Laxatives

- Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

Indications

Palliative care

Constipation

Sertraline

Section

Medicines for anxiety disorders

Indications

Therapeutic equivalent to [fluoxetine](#) for

Generalised anxiety disorder

Sevoflurane

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Silver diamine fluoride

Section

Dental medicines and preparations

- Local > Dental > Solution: 38% w/v

Indications

Dental caries

Silver nitrate

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 1%

Indications

Neonatal conjunctivitis or dacryocystitis

Silver sulfadiazine

Section

Dermatological medicines > Anti-infective medicines

- Local > Topical > Cream: 1%

Indications

Burns

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Simvastatin

Section

Lipid-lowering agents

- Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

Medicines for endocrine disorders

- Oral > Solid: 20 mg

Indications

Mixed hyperlipidaemia

Coronary atherosclerosis

Polycystic ovary syndrome

Smallpox vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Snake antivenom

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- .

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium calcium edetate

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

- Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na⁺ 154 mmol/L and Cl⁻ 154 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Sodium hyaluronate

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to [hypromellose](#) for

Keratoconjunctivitis sicca

Sodium hydrogen carbonate

Section

Solutions correcting water, electrolyte and acid-base disturbances

> Parenteral

- Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na⁺ 167 mmol/L and HCO₃⁻ 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na⁺ 1000 mmol/L and HCO₃⁻ 1000 mmol/L)

Indications

Acidosis

Sodium nitrite

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium nitroprusside

Section

Antihypertensive medicines

- Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

Indications

Hypertensive crisis

Sodium stibogluconate

Section

Antileishmaniasis medicines

- Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Sodium thiosulfate

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule

Dermatological medicines > Antifungal medicines

- Local > Topical > Solution: 15%

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Pityriasis versicolor

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

Chronic hepatitis C

Somatropin

Section

Medicines for endocrine disorders

- Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge

Indications

Hypoglycaemia without associated diabetes

Spectinomycin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Spironolactone

Section

Diuretics

- Oral > Liquid: 25 mg per 5 mL
- Oral > Solid > tablet: 25 mg; 12.5 mg

Medicines used in heart failure

- Oral > Solid > tablet: 25 mg

Indications

Oedema

Ascites

Heart failure

Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Streptokinase

Section

Thrombolytic medicines

- Parenteral > General injections > IV: 1.5 million IU in vial powder for injection

Indications

Acute myocardial infarction

Streptomycin (injection)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Succimer

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: 100 mg

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sulfacetamide

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Ointment: 10% (sodium salt)

Indications

Other specified conjunctivitis

Sulfadiazine

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 500 mg

Anti-infective medicines

- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

Indications

Toxoplasmosis

Bacterial infection of unspecified site

Sulfadimidine

Section

Anti-infective medicines

- Oral > Liquid: 500 mg per 5 mL
- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

Indications

Bacterial infection of unspecified site

Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 500 mg + 25 mg tablet
- Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 500 mg + 25 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Sulfamethoxazole + trimethoprim

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Oral > Solid > dispersible tablet: 100 mg + 20 mg
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule

Indications

Pneumocystosis

First choice

Infectious cystitis

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

Bacterial infection of unspecified site

Sulfasalazine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 500 mg

Anti-inflammatory medicines

- Oral > Solid: 500 mg
- Local > Rectal > Suppository: 500 mg
- Local > Rectal > Retention enema: 3 g per 100 mL

Indications

Rheumatoid arthritis, serology unspecified

Crohn disease site

Ulcerative colitis

Sumatriptan

Section

Medicines for cluster headache

- Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe

Medicines for acute migraine attacks

- Oral > Solid > tablet: 50 mg

Indications

Trigeminal autonomic cephalalgias

Migraine

Sunscreen, broad-spectrum

Section

Dermatological medicines

- Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50 .

Dermatological medicines > Sunscreens

- Topical:
- Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).

Indications

Xeroderma pigmentosum

Albinism or other specified genetically-determined hypomelanotic disorders

Suramin sodium

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IV: 1 g in vial

Antifilarials

- Parenteral > General injections > IV: 1 g in vial

Indications

Rhodesiense trypanosomiasis

Filariasis

Suxamethonium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)

Indications

Muscle relaxants

Tacalcitol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [calcipotriol](#) for

Psoriasis of unspecified type

Tacrolimus

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
- Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
- Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

Failure or rejection of transplanted organs or tissues

Tamoxifen

Section

Hormones and antihormones

- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Enterococcus*

Telmisartan + amlodipine

Section

Antihypertensive medicines

- Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

Essential hypertension

Telmisartan + hydrochlorothiazide

Section

Antihypertensive medicines

- Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

Essential hypertension

Temozolomide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection ◦ Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg	Other specified gliomas of brain Neuroblastoma, NOS Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites

Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 25 mg	Chronic hepatitis B

Tenofovir disoproxil fumarate

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B

Terbinafine

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Cream: 1% terbinafine hydrochloride ◦ Local > Topical > Ointment: 1% terbinafine hydrochloride	Fungal infection of the skin

Terbutaline

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to salbutamol for Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol for Asthma

Terizidone

Section

Antituberculosis medicines

- Oral > Solid > capsule: 250 mg

Indications

Therapeutic equivalent to [cycloserine](#) for

Multi-drug resistant *Mycobacterium tuberculosis*

Testosterone

Section

Androgens

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

Indications

Testicular dysfunction or testosterone-related disorders

Tetanus antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IM: 50000 IU in vial

Indications

Tetanus

Tetanus vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tetanus alone

Tetracaine

Section

Ophthalmological preparations > Local anaesthetics

- Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)

Indications

Local anaesthetics

Tetracycline

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)

Indications

Neonatal conjunctivitis or dacryocystitis

Other specified conjunctivitis

Infectious keratitis

Infectious blepharitis

Trachoma

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Bacterial infection of unspecified site

Thalidomide

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Thiamine

Section

Vitamins and minerals

- Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)
- Oral > Solid > tablet: 50 mg (hydrochloride)

Indications

Vitamin B1 deficiency

Thiopental

Section

General anaesthetics and oxygen > Injectable medicines

Indications

Therapeutic equivalent to propofol for

Anaesthetics and therapeutic gases

Ticagrelor

Section

Anti-platelet medicines

- Oral > Solid > tablet: 60 mg; 90 mg

Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

Tick-borne encephalitis vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against arthropod-borne viral encephalitis

Tigecycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

Timolol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

Indications

Ocular hypertension

Primary open-angle glaucoma

Tinidazole

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to [metronidazole](#) for

Amoebiasis

Tioguanine

Section

Cytotoxic medicines

- Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Tiotropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 18 µg in capsule
- Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler

Indications

Chronic obstructive pulmonary disease

Tirzepatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Tisagenlecleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for

Diffuse large B-cell lymphomas

Tislelizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion

Indications

Malignant neoplasms of urinary tract

Squamous cell carcinoma of oesophagus

Other specified malignant neoplasms of bronchus or lung

Hodgkin lymphoma

Tobramycin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

Tocilizumab

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
- Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Tolbutamide

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg

Indications

Type 2 diabetes mellitus

Torasemide

Section

Diuretics

Indications

Therapeutic equivalent to [furosemide](#) for

Anuria or oliguria

Therapeutic equivalent to [furosemide](#) for

Oedema

Medicines used in heart failure

Therapeutic equivalent to [furosemide](#) for

Heart failure

Toripalimab

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Squamous cell carcinoma of oesophagus

Malignant neoplasms of nasopharynx

Tramadol

Section	Indications
Opioid analgesics ◦ Oral > Liquid: 100 mg per mL (hydrochloride) ◦ Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release ◦ Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)	Chronic cancer pain

Trametinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Tranexamic acid

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Haemorrhage, not elsewhere classified

Trastuzumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Tremelimumab

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung

Triamcinolone hexacetonide

Section

Medicines for juvenile joint diseases

- Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial

Indications

Juvenile idiopathic arthritis

Triclabendazole

Section

Antischistosomes and other antitrematode medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

Paragonimiasis

Fascioliasis

Trihexyphenidyl

Section

Medicines for central nervous system disorders

- Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Medicines for parkinsonism

Indications

Parkinson disease

Therapeutic equivalent to [biperiden](#) for

Parkinson disease

Trimethoprim

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

First choice

Infectious cystitis

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of prostate

Tropicamide

Section

Diagnostic agents > Ophthalmic medicines

- Local > Ophthalmological > Solution (eye drops): 0.5%

Indications

Cycloplegic drug

Tropisetron

Section

Medicines for other common symptoms in palliative care

Antiemetic medicines

Indications

Therapeutic equivalent to [ondansetron](#) for

Palliative care

Therapeutic equivalent to [ondansetron](#) for

Nausea or vomiting

Tuberculin, purified protein derivative

Section

Immunologicals > Diagnostic agents

- Parenteral > Locoregional injections > Intradermal:

Indications

Mycobacterial diseases

Tubocurarine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)

Indications

Muscle relaxants

Typhoid vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against typhoid-paratyphoid alone

Ulipristal

Section

Oral hormonal contraceptives

- Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception

Umeclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

Urea

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 10%; 5%
- Local > Topical > Ointment: 10%; 5%

Dermatological medicines > Moisturizers

- Local > Topical > Cream: 5 per %

Indications

Xerosis cutis or asteatosis

Atopic eczema

Ustekinumab

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

Indications

Psoriasis of unspecified type

Valaciclovir

Section

Medicines for viral central nervous system infections

Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Therapeutic equivalent to [aciclovir](#) for

Varicella

Valganciclovir

Section

Other antivirals

- Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
- Oral > Solid > tablet: 450 mg (as hydrochloride)

Indications

Cytomegaloviral retinitis

Valproic acid (sodium valproate)

Section	Indications
Antiseizure medicines - Oral > Liquid: 200 mg per 5 mL - Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable) - Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule	Epilepsy or seizures Status epilepticus
Medicines for bipolar disorders Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)	Bipolar or related disorders

Valsartan + amlodipine + hydrochlorothiazide

Section	Indications
Antihypertensive medicines Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg	Essential hypertension

Vancomycin

Section	Indications
Watch group antibiotics - Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection - Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride) - Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection - Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection	First choice Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis Second choice Intestinal infections due to Clostridioides difficile Neutropaenia (high-risk) Other indications Methicillin resistant Staphylococcus aureus

Varenicline

Section	Indications
Medicines for nicotine use disorders Oral > Solid: 0.5 mg; 1 mg	Nicotine dependence

Varicella vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Vecuronium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

Indications

Muscle relaxants

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Verapamil

Section

Antianginal medicines

- Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Medicines for cluster headache

- Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)

Antiarrhythmic medicines

- Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
- Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Indications

Angina pectoris

Trigeminal autonomic cephalalgias

Supraventricular tachyarrhythmia

Vinblastine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate) ◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)	Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Vincristine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate) ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)	Other specified gliomas of brain Diffuse large B-cell lymphoma, not otherwise specified Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Retinoblastoma Malignant neoplasms of kidney, except renal pelvis

Vinorelbine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial ◦ Oral > Solid > capsule: 20 mg; 30 mg; 80 mg ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial	Rhabdomyosarcoma primary site Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast

Voriconazole

Section	Indications
Antifungal medicines ◦ Parenteral > General injections > IV: 200 mg in vial powder for injection ◦ Oral > Liquid: 40 mg per mL powder for oral liquid ◦ Oral > Solid: 50 mg tablet; 200 mg tablet	Chronic pulmonary aspergillosis Invasive aspergillosis

Warfarin

Section	Indications
Medicines affecting coagulation ◦ Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium) ◦ Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)	Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation Other specified diseases of arteries or arterioles

Water for injection

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous ◦ Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule	Unspecified appropriateness of dosing or administration without injury or harm

Whole blood

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Xylometazoline

Section

Ear, nose and throat medicines [c]

- Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL
- Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL

Indications

Nasal congestion

Yellow fever vaccine

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Zanubrutinib

Section

Targeted therapies

- Oral > Solid: 80 mg
- Oral > Solid > capsule: 80 mg

Indications

Mantle cell lymphoma

Therapeutic equivalent to **ibrutinib** for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Zinc sulfate

Section

Medicines for diarrhoea

- Oral > Solid > dispersible tablet: 20 mg (scored)

Indications

Diarrhoea

Zoledronic acid

Section

Medicines for endocrine disorders

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Supportive medicines

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Osteogenesis imperfecta

Malignant neoplasm metastasis in bone or bone marrow

Zuclopenthixol decanoate

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to fluphenazine for

Schizophrenia or other primary psychotic disorders